{"id":3148,"date":"2017-10-04T15:28:57","date_gmt":"2017-10-04T19:28:57","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\/"},"modified":"2026-09-24T00:09:53","modified_gmt":"2026-09-24T04:09:53","slug":"gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2017\/10\/04\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\/","title":{"rendered":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter  \u00e0 la Chardan Gene Therapy Conference  \u00e0 New York"},"content":{"rendered":"\n<strong>Paris, le 4 octobre \u00a02017, 7h30 CET \u2013<\/strong> GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que des membres de son management ont \u00e9t\u00e9 invit\u00e9s \u00e0 pr\u00e9senter \u00e0 la conf\u00e9rence suivante :\n\n<strong>Chardan Inaugural \u00a0Gene Therapy Conference <\/strong>\n<strong>Mardi 10 octobre \u00a02017 \u2013 New York (USA)<\/strong>\nThomas Gidoin, Directeur Administratif et Financier, pr\u00e9sentera le 10 octobre 2017 \u00e0 13h00, au Westin\nNew York Grand Central Hotel, et tiendra des rendez-vous investisseurs.\n<h2>\u00c0 propos \u00a0de GenSight Biologics<\/h2>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (Mitochondrial Targeting Sequence, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. Le candidat m\u00e9dicament le plus avanc\u00e9 de GenSight Biologics, GS010, est en Phase III pour le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), une maladie mitochondriale rare qui conduit \u00e0 une perte irr\u00e9versible de la vue chez les adolescents et les jeunes adultes. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intravitr\u00e9enne dans chaque \u0153il.\n","protected":false},"excerpt":{"rendered":"<p>Paris, le 4 octobre \u00a02017, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que des membres de son management ont \u00e9t\u00e9 [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[],"post-year":[],"class_list":["post-3148","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 la Chardan Gene Therapy Conference \u00e0 New York - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2017\/10\/04\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 la Chardan Gene Therapy Conference \u00e0 New York - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, le 4 octobre \u00a02017, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que des membres de son management ont \u00e9t\u00e9 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2017\/10\/04\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2017-10-04T19:28:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:09:53+00:00\" \/>\n<meta name=\"author\" content=\"editeur\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"editeur\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/10\\\/04\\\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/10\\\/04\\\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\\\/\"},\"author\":{\"name\":\"editeur\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\"},\"headline\":\"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 la Chardan Gene Therapy Conference \u00e0 New York\",\"datePublished\":\"2017-10-04T19:28:57+00:00\",\"dateModified\":\"2026-09-24T04:09:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/10\\\/04\\\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\\\/\"},\"wordCount\":300,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/10\\\/04\\\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/10\\\/04\\\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\\\/\",\"name\":\"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 la Chardan Gene Therapy Conference \u00e0 New York - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2017-10-04T19:28:57+00:00\",\"dateModified\":\"2026-09-24T04:09:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/10\\\/04\\\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/10\\\/04\\\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/10\\\/04\\\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 la Chardan Gene Therapy Conference \u00e0 New York\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\",\"name\":\"editeur\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"caption\":\"editeur\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 la Chardan Gene Therapy Conference \u00e0 New York - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2017\/10\/04\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 la Chardan Gene Therapy Conference \u00e0 New York - GenSight Biologics","og_description":"Paris, le 4 octobre \u00a02017, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que des membres de son management ont \u00e9t\u00e9 [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2017\/10\/04\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\/","og_site_name":"GenSight Biologics","article_published_time":"2017-10-04T19:28:57+00:00","article_modified_time":"2026-09-24T04:09:53+00:00","author":"editeur","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"editeur","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/10\/04\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/10\/04\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\/"},"author":{"name":"editeur","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a"},"headline":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 la Chardan Gene Therapy Conference \u00e0 New York","datePublished":"2017-10-04T19:28:57+00:00","dateModified":"2026-09-24T04:09:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/10\/04\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\/"},"wordCount":300,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/10\/04\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2017\/10\/04\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\/","name":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 la Chardan Gene Therapy Conference \u00e0 New York - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2017-10-04T19:28:57+00:00","dateModified":"2026-09-24T04:09:53+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/10\/04\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2017\/10\/04\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/10\/04\/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 la Chardan Gene Therapy Conference \u00e0 New York"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a","name":"editeur","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","caption":"editeur"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3148"}],"version-history":[{"count":2,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3148\/revisions"}],"predecessor-version":[{"id":6420,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3148\/revisions\/6420"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3148"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3148"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3148"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3148"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}